Results 171 to 180 of about 210,319 (212)
Some of the next articles are maybe not open access.
International Journal of Technology Assessment in Health Care, 2018
Introduction:Current practice in cost-effectiveness analysis (CEA) involves the estimation of the incremental cost-effectiveness ratio (ICER) between a new intervention and one alternative comparator reflecting the standard of care. As this focuses on pairwise comparisons, rather than considering the whole range of available alternatives at any given ...
Stefano Lucherini +2 more
openaire +1 more source
Introduction:Current practice in cost-effectiveness analysis (CEA) involves the estimation of the incremental cost-effectiveness ratio (ICER) between a new intervention and one alternative comparator reflecting the standard of care. As this focuses on pairwise comparisons, rather than considering the whole range of available alternatives at any given ...
Stefano Lucherini +2 more
openaire +1 more source
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System
PharmacoEconomics, 2017Spending on new healthcare technologies increases net population health when the benefits of a new technology are greater than their opportunity costs-the benefits of the best alternative use of the additional resources required to fund a new technology.The objective of this study was to estimate the expected incremental cost per quality-adjusted life ...
Laura Catherine Edney +3 more
openaire +3 more sources
Biometrics, 2006
SummaryWith medical costs escalating over recent years, cost analysis is being conducted more and more to assess economic impact of new treatment options. An incremental cost‐effectiveness ratio (ICER) is a measure that assesses the additional cost for a new treatment for each additional unit of effectiveness, such as saving 1 year of life.
Wang, Hongkun, Zhao, Hongwei
openaire +3 more sources
SummaryWith medical costs escalating over recent years, cost analysis is being conducted more and more to assess economic impact of new treatment options. An incremental cost‐effectiveness ratio (ICER) is a measure that assesses the additional cost for a new treatment for each additional unit of effectiveness, such as saving 1 year of life.
Wang, Hongkun, Zhao, Hongwei
openaire +3 more sources
The precision of regression-type estimator for incremental cost–effectiveness ratio
Journal of Statistical Computation and Simulation, 2012The estimation of incremental cost–effectiveness ratio (ICER) has received increasing attention recently. It is expressed in terms of the ratio of the change in costs of a therapeutic intervention to the change in the effects of the intervention. Despite the intuitive interpretation of ICER as an additional cost per additional benefit unit, it is a ...
Chien-Hua Wu, Shu-Mei Wan
openaire +1 more source
Incremental cost-effectiveness ratio (ICER)
Abstract The incremental cost-effectiveness ratio (ICER) is an analysis used to summarize the cost-effectiveness of a healthcare intervention. An overview of the ICER principles is followed by a description of ICER thresholds and the approach to calculating ICERs.Phil Ambery +2 more
openaire +1 more source
Heart, 2017
The article by Wouters and colleagues1 presents an exhaustive overview on how quality-adjusted life years (QALYs) can be used in cost-effectiveness analysis. In this framework, the authors also mention the incremental cost-effectiveness ratio (ICER), which is the parameter typically used to express the results of a cost-effectiveness study. The article,
Andrea, Messori, Sabrina, Trippoli
openaire +2 more sources
The article by Wouters and colleagues1 presents an exhaustive overview on how quality-adjusted life years (QALYs) can be used in cost-effectiveness analysis. In this framework, the authors also mention the incremental cost-effectiveness ratio (ICER), which is the parameter typically used to express the results of a cost-effectiveness study. The article,
Andrea, Messori, Sabrina, Trippoli
openaire +2 more sources
Journal of Clinical Oncology, 2015
6621 Background: Cost effectiveness of predictive biomarkers is currently assessed by Markov Chain (MC) simulations, requiring resources and expertise.
Anton Safonov +6 more
openaire +1 more source
6621 Background: Cost effectiveness of predictive biomarkers is currently assessed by Markov Chain (MC) simulations, requiring resources and expertise.
Anton Safonov +6 more
openaire +1 more source
Incremental cost-effectiveness ratio of the nationwide Public Access Defibrillation program in Japan
Resuscitation, 2013ufficient breathing correctly. The majority was afraid of exacerating the condition or causing death by intervening as a first esponder. The response rate at follow-up was 61%. There was a ignificant improvement in correct answers on themultiple-choice est (p< .001).
Aki Nagase +4 more
openaire +1 more source
Health Economics, 1999
It is becoming increasingly more common for a randomized controlled trial of a new therapy to include a prospective economic evaluation. The advantage of such trial-based cost-effectiveness is that conventional principles of statistical inference can be used to quantify uncertainty in the estimate of the incremental cost-effectiveness ratio (ICER ...
A R, Willan, B J, O'Brien
openaire +2 more sources
It is becoming increasingly more common for a randomized controlled trial of a new therapy to include a prospective economic evaluation. The advantage of such trial-based cost-effectiveness is that conventional principles of statistical inference can be used to quantify uncertainty in the estimate of the incremental cost-effectiveness ratio (ICER ...
A R, Willan, B J, O'Brien
openaire +2 more sources
Determination of incremental cost-effectiveness ratios of antitumor drugs
Farmaciya (Pharmacy), 2021Tat'jana Sergeevna Teptsova +4 more
openaire +1 more source